All In Biotech

Drug Trial Radar · NCT05668988

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

324

Actual

Start

Dec 13, 2022

Primary completion

Jan 16, 2026

Study completion Oct 31, 2027

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • sunvozertinibDrug

    orally, 300 mg, once daily until a treatment discontinuation criterion is met.

  • Pemetrexed+carboplatinDrug

    Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) per RECIST 1.1Time frame: Up to approximately 34 months after the first participant is randomized

Locations

154 sites in 15 countries. Site status is shown where the registry gives one.

  • OPN Healthcare, Inc.

    Glendale, California

  • Kaiser Permanente Medical Center

    Vallejo, California

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • D&H Cancer Research Center LLC

    Margate, Florida

  • BRCR Medical Center Inc.

    Plantation, Florida

  • NYU Langone Health

    New York, New York

  • NYU Laura & Issac Perlmutter Cancer Center at NYU Langone Health

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • OSU Brain & Spine Hospital

    Columbus, Ohio

  • Providence Portland Institute Franz

    Portland, Oregon

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • The University of Texas MD Anderson cancer center

    Houston, Texas

  • exas Oncology--McAllen

    Weslaco, Texas

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia

  • Centro Medico Austral

    Buenos Aires, Argentina

  • Consultorios Medicos Dr. Doreski - Fundacion Respirar

    Buenos Aires, Argentina

  • Fundacion Cenit Para El Estudio De Neurociencias

    Buenos Aires, Argentina

  • Instituto Argentino de Diagnositco y Tratamiento S.A

    Buenos Aires, Argentina

  • Fundación Estudios Clínicos

    Rosario, Argentina

  • Fundación Ars Médica

    San Salvador, Argentina

  • Concord Repatriation General Hospital

    Concord, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Australia

  • Prince of Wales Hospital

    Randwick, Australia

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Austria

  • Uniklinikum Salzburg Universitatsklinik fur Innere Medizin Ⅲ

    Salzburg, Austria

  • Universitair Ziekenhuis Antwerpen

    Edegem, Antwerp, Belgium

  • UZ Gent

    Ghent, Flanders, Belgium

  • Grand Hopital de Charleroi

    Charleroi, Hainaut, Belgium

  • Fundacao PIO XII - Hospital do Cancer de Barretos

    Barretos, Brazil

  • Hospital Evangelico de Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim, Brazil

  • Liga Norte Riograndense Contra o Câncer

    Natal, Brazil

  • Irmandade da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Brazil

  • Uniao Brasileira de Educacao e Assistencia - Hospital São Lucas da PUCRS

    Porto Alegre, Brazil

  • Instituto D'Or de Pesquisa e Ensino

    Recife, Brazil

  • Instituto D'Or de Pesquisa e Ensino

    Rio de Janeiro, Brazil

  • Instituto de Educacao, Pesquisa d Gestao em Saude

    Rio de Janeiro, Brazil

  • Instituto Nacional de Cancer - INCA

    Rio de Janeiro, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, Brazil

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.